Bernstein initiated coverage on Fresenius Medical
$FMS
Misc Health and Biotechnology Services
Health Care
Bernstein initiated coverage of Fresenius Medical with a rating of Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | Underperform → Neutral | BofA Securities | |
| 11/6/2024 | $25.60 | Buy | Berenberg |
| 1/8/2024 | Equal-Weight → Underweight | Morgan Stanley | |
| 11/24/2023 | Reduce → Hold | HSBC Securities | |
| 11/17/2023 | Hold → Buy | Societe Generale | |
| 8/14/2023 | Buy → Neutral | UBS | |
| 8/1/2023 | Neutral | Citigroup | |
| 7/12/2023 | Buy | Goldman |
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
BofA Securities upgraded Fresenius Medical from Underperform to Neutral
Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60
Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight
Total volume of the initial share buyback is up to EUR 1 billion over two yearsShare buyback to take place until August 10, 2027BAD HOMBURG, Germany, Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026.
Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth
Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life SciencesProvides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registryPaves way for advances in precision kidney disease care, novel therapies, and diagnosticsBAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis effo
Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.
BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany. Fresenius Medical Care succ
Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a
Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth
FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d
Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's historyExcellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growthIn 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlookThe company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent marginBAD HOMBURG, Germany, May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading pro
SC 13G - Fresenius Medical Care AG (0001333141) (Subject)
SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)
SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)